Related Experiment Video
Updated: Sep 11, 2026

Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking
Published on: August 6, 2013
The integrated Lei-CNS PBPK-PD model effectively predicts clozapine brain disposition and D2 receptor occupancy in
Mengxu Zhang1, Thomas I F H Cremers2,3, Vivi Rottschäfer4,5
1Division of Systems Pharmacology and Pharmacy, Predictive Pharmacology Group, Leiden Academic Centre of Drug Research, Leiden University, Leiden, The Netherlands.
Aim:
Clozapine, used for treatment-resistant schizophrenia, has a narrow therapeutic window and highly variable plasma pharmacokinetics (PK), necessitating careful monitoring. Direct measurement of unbound brain PK in humans is unethical. To develop a physiologically based pharmacokinetic-pharmacodynamic (PBPK-PD) model to predict clozapine brain extracellular fluid (brainECF) PK in rats and humans and D2 receptor occupancy (RO) in humans.
Methods:
A previously developed rat CNS PBPK model (LeiCNS-PK3.5), containing brain metabolism, was extended to include active blood-brain barrier (BBB) influx transport and neutral lipid binding (LeiCNS-PK3.6). LeiCNS-PK3.6 was validated against observed brainECF clozapine concentrations in rats. For human translation, species-specific transporter and enzyme parameters were applied. A receptor binding kinetics model, with association and dissociation rate constants, was developed to predict D2 RO based on unbound brainECF clozapine concentrations and validated using PET-derived clinical data.
Results:
The LeiCNS-PK3.6 model significantly improved the prediction accuracy of brainECF clozapine PK in rats compared with previous versions. In humans, predicted brainECF concentrations aligned with expected therapeutic ranges. The PBPK-PD model accurately predicted D2 RO in most patients, suggesting polymorphisms, smoking and dissociation rate constant (koff) may affect prediction accuracy.
Conclusions:
The integrated CNS PBPK-PD model effectively predicts clozapine brain disposition and D2 RO in humans. This framework offers a valuable tool to explore inter-individual variability (e.g., CYP1A2 polymorphisms, smoking and koff), supporting personalized dosing strategies and improved safety in clozapine therapy.
Related Concept Videos
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Physiological Pharmacokinetic Models: Assumption with Protein Binding
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model
Pharmacokinetic–Pharmacodynamic Relationship: Model Components
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Pharmacodynamic Models: Linear Concentration–Effect Model

